On December 21, 2022 Guided Therapeutics, Inc. or the "Company" (OTCQB: GTHP), the maker of LuViva, a rapid and painless cervical cancer detection system based on the Company’s patented biophotonic technology, announced today it had executed a Clinical Trial Agreement with a prestigious academic medical institution (Press release, Guided Therapeutics, DEC 21, 2022, View Source [SID1234625516]). The clinical trial is aimed at achieving FDA approval for LuViva and is expected to involve approximately 400 women at up to three medical institutions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Negotiating and signing the Clinical Trial Agreement is the final step prior to starting the study," said Gene Cartwright, CEO of Guided Therapeutics. "We look forward to the start of the study early next year and planned completion before the end of 2023."